中国援莱医疗队队长吴辉分别与马塞卢地区医院院长马苏帕及恩特塞克医院院长莫罗益签署药械交接证 书。此次交接的药械涵盖一次性麻醉穿刺包、针灸针具以及骨科和外科耗材，以及数十种莱索托当地紧 缺的专科药物，总价值二十多万元人民币。这些物资预计惠及莱索托首都及周边地区数十万居民。 吴辉表示："每一箱物资都经过精心调配，旨在精准对接莱方临床需求。我们期待这些药械能尽快投入 临床应用，为守护莱索托人民健康发挥实效。"(完) 当地时间12月30日，中国(湖北)第19批援莱索托医疗队药械捐赠仪式在莱索托马塞卢地区医院举行。(左 昌俊 摄) 中新网约翰内斯堡12月31日电 马塞卢消息：当地时间12月30日，中国(湖北)第19批援莱索托医疗队药械 捐赠仪式在马塞卢地区医院举行。中国驻莱索托大使杨晓坤、莱索托卫生部常务秘书恩特内、中国援莱 医疗队队长吴辉、马塞卢地区医院院长马苏帕及恩特塞克医院院长莫罗益等共同出席了仪式。 中国驻莱索托大使杨晓坤在仪式上发表讲话时称，中莱两国传统友谊深厚，医疗卫生合作是两国关系的 重要组成部分。中国长期向莱索托派遣医疗队，并持续提供力所能及的帮助，这充分体现了中国人民对 莱索托人民的真挚情谊以及中国政 ...

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Company Overview: Catalyst Pharmaceutical (CPRX) - Catalyst Pharmaceutical currently holds a Momentum Style Score of A, indicating strong momentum characteristics [2] - The company has a Zacks Rank of 2 (Buy), suggesting it is positioned for potential outperformance in the market [3] Price Performance - CPRX shares have increased by 1.92% over the past week, while the Zacks Medical - Drugs industry remained flat [5] - Over the past month, CPRX's price change is 8.02%, outperforming the industry's 3.76% [5] - In the last quarter, shares of CPRX have risen by 18.84%, and over the past year, they have gained 55.3%, compared to the S&P 500's increases of 2.37% and 14.4%, respectively [6] Trading Volume - The average 20-day trading volume for CPRX is 1,094,588 shares, which serves as a bullish indicator when combined with rising stock prices [7] Earnings Outlook - In the past two months, four earnings estimates for CPRX have been revised upwards, while none have been revised downwards, leading to an increase in the consensus estimate from $2.15 to $2.25 [9] - For the next fiscal year, three estimates have moved up, while one has been revised down [9] Conclusion - Considering the strong momentum indicators and positive earnings outlook, CPRX is identified as a 2 (Buy) stock with a Momentum Score of A, making it a potential candidate for near-term investment [11]